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Abstract
Background: Breast cancer is the most fatal malignant cancer among women, the conventional therapeutic
modalities of it are limited. Morusin possesses cytotoxicity against some cancer cells in vitro. The purpose of this
study is to test the growth inhibition effect of morusin on human breast cancer growth in vitro and in vivo and to
explore the potential mechanism of its action.
Methods: The growth inhibition effect of morusin on human breast cancer cells in vitro and in vivo were tested by
cell cytotoxicity, colony formation inhibition, adipogenic differentiation, apoptosis induction, and tumor growth
inhibition in vivo assays. The potential molecular mechanisms underlying the growth inhibition effect of morusin
on human breast cancer cells in vitro and in vivo were investigated with Western blotting evaluation of expression
levels of transcription factors, C/EBPβ and PPARγ, adipogenic and apoptotic proteins in morusin treated breast
cancer cells and tumor tissues.
Results: Morusin inhibited breast cancer cells growth in vitro and in vivo; it induced adipogenic differentiation,
apoptosis and lipoapoptosis of cancer cells.
Conclusions: Morusin has the potential to inhibit human breast cancer cell growth in vitro and in vivo through
C/EBPβ and PPARγ mediated lipoapoptosis.
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Background
Breast cancer is one of the most prevalent cancers and
the leading cause of cancer death among women world-
wide [1]. Despite the significant advances in breast can-
cer treatment modalities and improvement of patients’
survival and quality of life in recent decades, its inci-
dence and mortality are increasing steadily, especially in
developing countries [1–3]. Currently, the conventional
therapeutic strategies such as surgery, radiotherapy, and
chemotherapy are limited treatment options for breast
cancer. Although breast cancer patients with estrogen
receptor positive (ER+) have a better outcome after
endocrine therapy, one-third of them are not sensitive to
Tamoxifen, and the rest of them have a risk of relapse
[4, 5]; The subtype, “Triple Negative Breast Cancer”
(TNBC), is more aggressive and resistance to available
treatments, there has no available therapeutics for it [6, 7].
Therefore, the identification of effective chemopreventive
agents and development of neoadjuvant chemotherapies
with alternative strategic options are crucial for ER+
breast cancer and TNBC [8–11].
Previous investigations revealed natural products
process anticancer activity and selectivity of anti-cancer
agents [12, 13], flavonoids provide a diversity of antican-
cer compounds which can be used for breast cancer pre-
vention and/or treatment [14].
Morusin is a prenylated flavonoid derived from the
root bark of Morusaustralis (Moraceae) [15] and branch
bark of Ramulus mori [16], possesses anti-oxidant and
anti-inflammatory activities [17]. It exhibited cytotoxicity
against some human cancer cells in vitro, including colo-
rectal cancer [15], prostate cancer [17], breast cancer,
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cervical cancer and liver cancer cells [18, 19], prevents
neuronal cells from nitrosative stress-mediated cell death
[20], and inhibits the tumor growth of murine hepato-
carcinoma in vivo without side effects [11]. Our previous
studies showed that morusin inhibited the proliferation
and migration of human cervical CSCs through reduc-
tion of NF-κBp65 activity and apoptosis induction [21],
suppressed glioblastoma stem cell growth in vitro and
in vivo through stemness attenuation, adipocyte transdif-
ferentiation and apoptosis induction [22].
In light of these findings, it could be assumed that
morusin might serve as a novel therapeutic agent for
cancer therapy, But its anticancer efficiency and profile
needs to be confirmed further, and the mechanism of ac-
tion is elusive [17–22]. Therefore, in the present study,
we investigated the growth inhibition effect of morusin
on human breast cancer cells in vitro and in vivo and




DMEM media and fetal bovine serum (FBS) were
purchased from Invitrogen (Shanghai, China). Trypsin,
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT), DMSO and other chemicals and re-
agents were obtained from Sigma-Aldrich (Shanghai,
China). Morusin was purchased from Chengdu Biopurify
Phytochemicals Ltd. (Chengdu, China, purity ≥98 %
HPLC).
Cell line and culture
Human normal mammary epithelial cells, MCF-10A,
murine breast cancer cells (4 T1 and EMT6) and human
breast cancer cells (MCF-7 and MDA-MB-231) were ob-
tained from Shanghai Cell Biology Institute of Chinese
Academy of Sciences (Shanghai, China), and were main-
tained in DMEM medium with 10 % fetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 μg/ml) at
37 °C in the presence of 5 % CO2.
Cytotoxicity assay (MTT)
The cytotoxicity of morusin against human normal
mammary epithelial cells and murine breast cancer cells
(4 T1 and EMT6) and human breast cancer cells (MCF-7
and MDA-MB-231) was tested by modified MTT assay
[23]. Briefly, human normal mammary epithelial cells
MCF-10A, and breast cancer cells, MCF-7 and MDA-
MB-231, (1 × 103/well) were seed in 100 μl of medium/
well in 96-well plates. After overnight incubation, the cells
were then treated with various concentrations of morusin
(1, 2, 4, 6 and 8 μg/ml), each concentration containing 3
wells. After treatment with morusin for 1, 2, 3, 4, and
5 days, 20 μl MTT (pH 4.7) was added to each well, and
cultivated for another 4 h, 100 μL of 10 % SDS/0.01 N
HCl was added and incubated at 37 °C overnight to
dissolve the formazan. Absorbance was measured at
570 nm, the effect of morusin on the viabilities of normal
mammary epithelial cells, MCF-10A and breast cancer
cells, MCF-7 and MDA-MB-231 were expressed as the %
cytoviability, using the following formula: % cytoviability =
A570 of treated cells/A570 of control cells × 100 % [23, 24],
Three independent experiments were performed.
Colony formation inhibition assay
The clonogenic potential of breast cancer cells was deter-
mined by seeding 300 human breast cancer cells per well
in 6-well plates, the cells were incubated for approxi-
mately 24 h, and then treated with 1, 2, and 3 μg/ml of
morusin, respectively. After 12 days of incubation, the
cells were stained with 0.5 % crystal violet in absolute
ethanol and colonies with >50 cells were counted under
dissection microscope. Three independent experiments
were conducted, each in triplicate.
DAPI staining apoptotic cells
Apoptotic morphology-nuclear chromatin condensation
was examined with DAPI staining. MCF-7 and MDA-MB-
231 cells were seeded in 6-well plates. After incubation
overnight, cells were treated with different concentrations
of morusin (4, 6, 8 μg/ml) for 48 h. Subsequently, cells
were harvested, fixed in 4 % paraformaldehyde, treated
with 0.25 % Triton X-100 in TBS for 15 min at room
temperature and stained with 50 μl DAPI (4 mg/mL,
Sigma, Aldrich) for 30 min at room temperature. After
washing with PBS, samples were stored in the dark at 4 °C
and examined under a fluorescence microscope [25], three
independent experiments were conducted.
Annexin V-FITC/PI double staining apoptotic cells
Detection of apoptotic cells was performed using the
Annexin V-FITC/PI apoptosis detection kit (Beyotime
Biotech, Shanghai, China) according to manufacturer’s
instructions. Briefly, cancer cells treated with 4, 6, and
8 μg/ml of morusin, respectively, for 36 h were washed
with PBS and stained simultaneously with FITC-
conjugated Annexin V and PI at room temperature for
15 min in the dark. The apoptotic cells were measured
using a FACScalibur flow cytometer and Cell Quest Pro
software (BD Biosciences, Shanghai, China). Three inde-
pendent experiments were performed.
Cell cycle analysis (FCM)
Cell cycle distribution was analyzed by flow cytometry
(FCM). Briefly, 1 × 106 cells were harvested from the
control and breast cancer cells treated with 4, 6, 8 μg/ml
of morusin for 36 h, washed twice with PBS and fixed in
70 % ice-cold ethanol for 1 h. The sample was then
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concentrated by removing ethanol and treated with 1 %
(v/v) Triton X-100 and 0.01 % RNase for 10 min at
37 °C. Cellular DNA was stained with 0.05 % propidium
iodide for 20 min at 4 °C in darkness. Cell cycle distribu-
tion were analyzed with FCM (Cytomics™ FC500,Beckman
Coulter) and MultiCycle software package (Phoenix,
USA). All data represents the results from three independ-
ent experiments.
Tumor growth inhibition test in vivo
15 six-week-old female nude mice were inoculated with
2 × 106 human breast cancer cells (MCF-7) subcutane-
ously. After 5 days of tumor cell inoculation, tumor
bearing mice were randomized into three groups, each
having five mice. Two treatment group mice were
injected with 5 and 10 mg/kg of morusin i.p. three times
weekly for 4 weeks, respectively, and the control mice
were injected with DMSO. During the experiment, mice
were weighted, and tumor volumes were measured
weekly using calipers and their volumes were calculated
using a standard formula (length × width2 × 0.5) [26]. At
the end of experiment, the mice were sacrificed by
carbon dioxide asphyxiation; tumor masses were dis-
sected, and weighed. The tumor inhibitory rates were
calculated using the following formula: tumor inhibitory
rate(%) = (mean tumor weight of the control mice −
mean tumor weight of the treated mice)÷ mean tumor
weight of the control mice × 100 %. The experiment was
performed under standard conditions according to the
guidelines of the Institutional Animal Care and Use
Committee of Sichuan University.
Oil Red O staining
Breast cancer cells treated with 2, and 4 μg/ml of moru-
sin for 72 h, respectively, the cells were fixed with 100 %
methanol, washed in PBS; cryostat sections of the con-
trol and morusin treated tumor tissues were prepared
regularly. Both the cells and cryostat sections of tumor
tissues were stained with Oil Red O stain for 20 min at
room temperature [27]. After incubation, slides were dif-
ferentiated with an 85 % propylene glycol solution for
1 min, rinsed in water, and counterstained with Mayer’s
Hematoxylin and observed under microscope.
Western blot analysis
Both morusin treated breast cancer cells and tumor tis-
sues were lysated with RIPA lysis buffer, centrifuged, the
supernatants were collected and quantified with UV
Fig. 1 Morusin inhibited breast cancer cell growth and colony formation in vitro. a Human normal mammary epithelial cells (MCF-10A). b Murine
breast cancer cells (4 T1). c Murine breast cancer cells (EMT6). d Human breast cancer cells (MCF-7). e Human breast cancer cells (MDA-MB-231).
f Morusin inhibited human breast cancer cell colony formation. *P < 0.05, **P < 0.01. Three independent experiments were performed
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spectrophotometer. Samples containing 30 μg protein
were mixed with loading buffer (5×), boiled for 5 min,
separated by 12 % SDS-PAGE, transferred PVDF mem-
branes using a semi-dry blotting apparatus (Bio-Rad,
Hercules, CA, USA), and then blocked in 5 % non-fat
milk at RT for 1 h. The PVDF membranes were incu-
bated with primary antibodies of rabbit anti-C/EBP
β,rabbit anti-PPARγ, rabbit anti-adipsin D,rabbit anti-
perilipin A + B, rabbit anti-Bcl-2, rabbit anti-Bax, rabbit
anti-active caspase-3 and rabbit anti-β-actin (Beijing
Biosynthesis Biotechnology Co., LTD, Beijing, China)
diluted 1:300. Antibody recognition was detected with
peroxidase-conjugated goat anti-rabbit IgG (H + L) sec-
ondary antibody (Zhongshan Goldenbridge Biotechnology
Co., LTD, Beijing, China) used at 1:6000 dilutions,
antibody-bound proteins were detected by Chemilumines-
cent HRP Substrate (Milipore Corporation, Billera, USA)
and western blotting analysis system (Universal Hood II,
Bio-Rad, USA), and normalized to β-actin and semi-
quantified using the ChemiDocTM XRS (Bio-Rad, USA).
Statistical analysis
The data were expressed as mean ± standard deviation
(Mean ± SD). All data were analyzed using the software
SPSS V 16.0. Independent sample t-test was used to
analyze the statistical difference. Statistical significance
was defined as p < 0.05 for all tests.
Results
Morusin inhibits murine and human breast cancer cell
proliferation
The proliferation inhibition effect of morusin on hu-
man normal mammary epithelial cells (MCF-10A) and
breast cancer cells is shown in Fig. 1. Morusin exhibited a
dose- and time-dependent inhibitory effect on murine and
Fig. 2 DAPI stained apoptotic cells in morusin treated MCF-7 and MDA-MB-231 breast cancer cells. a DAPI stained apoptotic cells in morusin
treated MCF-7 cells. b The histogram shows that there was significant increase of AO/EB stained apoptotic cells in morusin treated MCF-7 cells.
c DAPI stained apoptotic cells in morusin treated MDA-MB-231 cells. d The histogram shows that there was significant increase of DAPI stained
apoptotic cells in morusin treated MDA-MB-231 cells. *P < 0.05, **P < 0.01. Three independent experiments were performed
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human breast cancer cells (p < 0.01). IC50 was 9.48 μg/ml
for normal mammary epithelial cells (MCF-10A); 2.03 and
1.87 μg/ml for murine breast cancer cells (4 T1 and
EMT6); and 2.71 and 3.86 μg/ml for human breast cancer
cells (MCF-7 and MDA-MB-231), respectively, the max-
imal inhibition of cell growth (>80 %) was obtained at
8 μg/ml (Fig. 1b, c, d, e).
Morusin inhibits breast cancer cell colony formation
Colony formation rates of untreated MCF-7 and
MDA-MB-231breast cancer cells were 54.83 ± 4.75
and 33.33 ± 1.04 %, respectively. After treatment with
1, 2, and 3 μg/ml of morusin, Colony formation
rates of MCF-7 cells were 46.67 ± 4.04, 36.50 ± 3.50 and
18.50 ± 1.50 %, respectively; the rates of MDA-MB-23 cells
were 19.33 ± 0.58, 15.50 ± 0.87 and 10.33 ± 1.10 %, respect-
ively. Dose-dependent colony-forming inhibitory effect
was observed in both MCF-7 and MDA-MB-231breast
cancer cells (Fig. 1f).
Apoptotic cell detection by DAPI staining
The cells with condensed chromatin and stained bright
with DAPI morphologically were apoptotic cells. Apoptotic
cells in the untreated human breast cancer cells MCF-7
and MDA-MB-231 were 1.11 ± 0.37 % and 1.12 ± 0.47 %,
respectively. After treatment with 4, 6, 8 μg/ml of morusin
for 48 h, the apoptotic cells in breast cancer cells, MCF-7
were 6.7 ± 4.09, 15.70 ± 3.63, and 22.50 ± 4. 3 %, respect-
ively; and in MDA-MB-231 cells, the apoptotic cells were
5.9 ± 0.51, 13.5 ± 1.4, 20.5 ± 1.3 %, respectively. The apop-
totic cells in morusin treated breast cancer cells were in-
creased significantly in a dose-dependent manner (p < 0.01,
Fig. 2).
Apoptotic cell detection by FCM
Annexin-V-FITC/PI double staining assay and FCM
analyses showed that apoptotic cells in the untreated hu-
man breast cancer cells MCF-7 and MDA-MB-231 were
4.70.11 ± 1.41 and 3.90 ± 1.27 %, respectively, after
Fig. 3 Annexin V-FITC stained apoptotic cells. a Morusin induces apoptosis of MCF-7 cells. b The histogram shows the significant increase of
apoptotic cells in MCF-7 cells after treatment with morusin in a dose dependent manner. c Morusin induces apoptosis of MDA-MB-231 cells.
d The histogram shows the significant increase of apoptotic cells in MDA-MB-231cells after treatment with morusin in a dose dependent manner.
*P < 0.05, **P < 0.01. Three independent experiments were performed
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treatment with 4, 6, 8 μg/ml of morusin for 48 h, the
apoptotic cells in the treated cancer cells increased
significantly (p < 0.01, Fig. 3), in a dose-dependent
manner.
Flow cytometric analysis of cell cycle distribution
Cell cycle analysis was performed in MCF-7 and MDA-
MB-231 cells after morusin treatment. Morusin treat-
ment increased the cell population in G0/G1 phase and
decreased the cell population in S phase in a dose
dependent manner in both MCF-7 and MDA-MB-
231cancer cells (Fig. 4).
Morusin inhibited breast growth in vivo
The result of tumor growth inhibition of morusin on hu-
man breast cancer generated from MCF-7 cells is shown
in Fig. 5. To evaluate the growth inhibition effect of
morusin on human breast in vivo, human breast cancer
bearing-mice were injected with 5 and 10 mg/kg of
morusin i. p., 3 times weekly for 4 weeks. Morusin re-
tarded the growth of breast cancer significantly (p < 0.01,
(Fig. 5b). Mean tumor weight of the control mice was
1.14 ± 0.30 g, and those of the mice administrated
with 5 and 10 mg/kg of morusin were 0.61 ± 0.23 and
0.41 ± 0.10 g, respectively (Fig. 5c), tumor inhibitory
Fig. 4 Morusin induced cell cycle arrest of human breast cancer cells. a Morusin induces cell cycle arrest of MCF-7 cells. b The histogram shows
the significant increase of cell population in G0/G1 phase and decrease in S phase in a dose dependent manner in morusin treated MCF-7 cells
c Morusin induces cell cycle arrest of MDA-MB-231 cells. d The histogram shows the significant increase of cell population in G0/G1 phase and
decrease in S phase in a dose dependent manner in morusin treated MDA-MB-231 cells. *P < 0.05, **P < 0.01. Three independent experiments
were performed
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rates were 46.5 % (p < 0.05), and 64.1 % (p < 0.01), re-
spectively (Fig. 5d). No obvious evidence of toxicity was
observed in treated animals by comparing the body weight
increase (Fig. 5a), histopathological changes of major or-
gans of both the control and treated animals.
Adipocyte-like differentiation effect of morusin on breast
cancer cells
Fat vacuole accumulation was observed in morusin
treated breast cancer cells and tumor tissues, staining of
these cells with oil red O showed that these vacuoles
were lipid droplets and located in the cytoplasm around
the nucleus, lipid droplets were increased in a dose-
dependent manner (Fig. 6).
Morusin affected adipogenic and apoptotic protein
expressions in vitro and in vivo
To explore the potential molecular mechanisms under-
lying the growth inhibition effect of morusin on human
breast cancer cells in vitro and in vivo, transcription fac-
tors C/EBP β and PPARγ, adipogenic and apoptotic pro-
teins in morusin treated breast cancer cells and tumor
tissues were evaluated with Western blotting. Expres-
sions of transcription factors C/EBP β and PPARγ, adi-
pogenic proteins including adipsin D and perilipin, were
increased significantly (Fig. 7, p < 0.05); In expressions of
apoptotic proteins, Bcl-2 were decreased, Bax and
active caspaes-3 were increased significantly (Fig. 8,
p < 0.05) in a dose-dependent manner in both of morusin
treated breast cancer cells and tumor tissues compared
with the controls.
Discussion
Breast cancer is most common malignant cancer,
remains a leading cause of cancer-related death inter-
nationally. It is considered as a major public health
problem around the world [1, 2, 28]. Its increasing inci-
dence and mortality urgently needs identification and
development of new and effective treatment options and
chemopreventive strategies [8–11].
Flavonoids are present everywhere in nature, different
flavonoids exhibited specific anticancer activities and
could be purposely used both in cancer treatment as
well as in chemoprevention [29], and some flavonoids
are useful for prevention or treatment of breast cancer
[14]. Prenylated flavonoids are a unique class of naturally
occurring flavonoids that exist especially for the plant’s
self-defensive function, the prenylation brings prenylated
flavonoids with antibacterial, anti-inflammatory, antioxi-
dant, cytotoxicity and estrogenic activities, thus, their
bioactivities and action mechanisms need to be further
investigated [30].
Morusin is a prenylated flavonoid isolated from the
root bark of Morusaustralis and branch bark of Ramulus
mori [15, 16], it can also be synthesized [17]. Existed
studies showed morusin processes cytotoxicity against
some human cancer cells in vitro [15–21] with little side
effects [16, 17]. However, its anticancer efficiency and
Fig. 5 Morusin inhibited human breast cancer growth initiated from MCF-7 breast cancer cells in vivo. a Body weight changes of each group after
morusin treatment. b Tumor volume changes of each group after morusin treatment. c Tumor masses of each group. d The histogram shows that
there was a significant difference of mean tumor weight of each morusin treated group compared with the control. *P < 0.05, **P < 0.01
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profile in vivo needs to be confirmed and its mechanism
of activity remains to be elucidated [17–22].
In the present study, murine and human breast cancer
cells, including ER+ breast cancer cells (MCF-7, ERα+)
and TNBC cells (MDA-MB-231 and 4 T1) were treated
with morusin, the cell proliferation of cancer cells were
suppressed in dose and time-dependent manner (Fig. 1),
the colony growth potential of cancer cells was inhibited
in a dose-dependent manner (Fig. 1d, p < 0.01), and little
cytotoxicity to normal mammary epithelial cells was
noted (Fig. 1a).
Inducing apoptosis and cell cycle arrest are two main
strategies for cancer treatment, many anticancer agents
target rapidly cycling tumor cells, induce them cell cycle
arrest and apoptotic death, and inhibit tumor growth
in vivo [30–32].
After treatment with morusin, apoptotic cells were
increased significantly in a dose-dependent manner
(p < 0.01, Figs. 2 and 3), cell cycle arrest of morusin
treated cancer cells was verified with flow cytometry ana-
lysis, the cell numbers in G0/G1 phases were increased
and decreased in S phase significantly (p < 0.01, Fig. 4) in
morusin treated cancer cells, which are the important
hallmarks of apoptosis [33–35].
In vivo experiment,morusin supressed the growth of
human breast cancer in vivo, reduced the volume and
weight of tumor masses significantly (p < 0.01, Fig. 5),
without evident toxicity [16, 22]. It is suggested that
morusin might have potential anticancer activity on hu-
man breast cancer in vivo.
Furthermore, when breast cancer cells were exposed to
low concentrations of morusin (2–6 μg/ml) in vitro, most
cells survived and differentiated into adipocyte-like cells.
In addition, focal adipogenetic differentiation was detected
in morusin treated breast cancer tissues (Fig. 6).
To explore the molecular mechanisms of the growth
inhibition effect of morusin on human breast cancer
cells in vitro and in vivo, transcription factors C/EBP β
Fig. 6 Adipogenic differentiation effect of morusin on human breast cancer cells. a Morusin induces adipocyte-like differentiation of MCF-7 breast
cancer cells. b Morusin induces adipocyte-like differentiation of MDA-MB-231 breast cancer cells. c Morusin induces adipogenic differentiation of
MCF-7 breast cancer cells in vivo
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and PPARγ, adipogenic and apoptotic proteins in morusin
treated cancer cells and tumor tissues were analyzed with
Western blotting. After morusin treatment, transcription
factors C/EBP β and PPARγ, adipogenic proteins in-
cluding adipsin D and perilipin were increased sig-
nificantly (p < 0.05, Fig. 7) both in morusin treated
Fig. 7 Adipogenic protein expressions in morusin treated human breast cancer cells and tumor tissues. a Western blot analysis of transcription
factors C/EBP β and PPARγ and adipogenic protein expressions in morusin treated MCF-7 cells. b The histogram shows that there was significant
increase of C/EBP β, PPARγ, adipsin D, and perilipin expressions in a dose dependent manner in morusin treated MCF-7 cells. c Western blot
analysis of transcription factors C/EBP β and PPARγ and adipogenic protein expressions in morusin treated MDA-MB-231 cells. d The histogram
shows that there was significant increase of C/EBP β, PPARγ, adipsin D, and perilipin expressions in a dose dependent manner in morusin treated
MDA-MB-231 cells. e Western blot analysis of transcription factors C/EBP β and PPARγ and adipogenic protein expressions in morusin treated
breast tumor tissues. f The histogram shows that there was significant increase of C/EBP β, PPARγ, adipsin D, and perilipin expressions in a dose
dependent manner in morusin treated tumor tussues. *P < 0.05, **P < 0.01. Three independent experiments were performed
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cancer cells and tumor tissues, which were widely used
molecular markers of adipocyte differentiation [36–39]; In
apoptotic protein expression, anti-apoptosis protein, Bcl-2
were decreased, pro-apoptosis protein, bax and active
caspaes-3 were increased significantly (p < 0.05, Fig. 8),
which play important roles in the regulation of
mitochondrial-mediated apoptosis [40, 41].
CCAAT-enhancer binding protein β (C/EBPβ) plays a
pivotal role in terminal adipocyte differentiation, it is in-
duced early to transactivate the expression of two master
Fig. 8 Apoptotic protein expressions in morusin treated human breast cancer cells and tumor tissues. a Western blot analysis of apoptotic protein
expressions in morusin treated MCF-7 cells. b The histogram shows that there was significant increase of Bax and active caspaes-3 and decrease of
Bcl-2 expressions in a dose dependent manner in morusin treated MCF-7 cells. c Western blot analysis of apoptotic protein expressions in morusin
treated MDA-MB-231 cells. d The histogram shows that there was significant increase of Bax and active caspaes-3 and decrease of Bcl-2 expressions in
a dose dependent manner in morusin treated MDA-MB-231 cells. e Western blot analysis of apoptotic protein expressions in morusin treated breast
tumor tissues. f The histogram shows that there was significant increase of Bax and active caspaes-3 and decrease of Bcl-2 expressions in a dose
dependent manner in morusin treated tumor tussues. *P < 0.05, **P < 0.01. Three independent experiments were performed
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transcription factors, C/EBPα and peroxisome proliferator-
activated receptor γ (PPARγ) [42]. Besides, C/EBPβ is also
a transcription factor necessary for growth and differenti-
ation of mammary gland and plays a critical role in mam-
mary gland development and breast cancer progression
[43, 44]. Its expression decrease was associated with
shorter overall survival of breast cancer patients and
increase of lung metastasis of mouse breast cancer cells
[44, 45]. Herein, morusin might act as an agonist of
C/EBPβ and PPARγ, upregulate expressions of C/EBPβ
and PPARγ, activated the cascade of adipogenic differenti-
ation of breast cancer cells.
Moreover, PPARγ activation is associated with differenti-
ation, proliferation inhibition of the normal and malignant
cells [46] and reversal of malignant phenotype of breast
cancer cells [47]. It plays potential roles in the apoptosis of
many types of cancer cells; its expression was increased
simultaneously when apoptosis occurred [47–51].
In this experimental study, morusin treatment forced
breast cancer cells differentiated into adipocyte-like cells,
a lot of lipid droplets were accumulated increasingly in
these adipogenic differentiating cells, unlimited accumu-
lation of lipid droplets in the differentiating cancer cells
results in apoptotic cell death of the differentiated can-
cer cells due to lipoptosis [52, 53]. Lipoptosis induction
might be a novel approach for cancer therapeutic strat-
egy, but no agents, which directly induce lipoapoptosis
of cancer cells, have thus far been identified [52–54].
Combined with the findings in the present study, it
could be assumed that morusin might be an effective
agent on inducing adipogenic differentiation and lipoa-
poptosis of breast cancer cells through modulating the
pathways of adipogenic differentiation and apoptosis or
lipoapoptosis.
Conclusions
In summary, morusin has the potential to inhibit human
breast cancer cells growth in vitro and in vivo through
C/EBPβ and PPARγ mediated adipogenic differentiation
and lipoapoptosis induction, it might serve as a novel
therapeutic agent for the treatment and/or prevention of
human breast cancer, including ER+ breast cancer and
TNBC, and need to be investigated further.
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